Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
beta thalassemia
Pharma
FDA approves Vertex, CRISPR's Casgevy for beta thalassemia
Vertex and CRISPR have scored an FDA approval for their gene-editing therapy Casgevy to treat transfusion-dependent beta thalassemia (TDT).
Kevin Dunleavy
Jan 16, 2024 3:40pm
Agios charts broad path for oral thalassemia med after trial win
Jan 3, 2024 10:49am
In 'historic' nod, UK signs off on Vertex, CRISPR's gene therapy
Nov 16, 2023 11:45am
Vertex teases launch plans for first CRISPR gene editing therapy
Feb 8, 2023 2:55pm
ASH: Bluebird's lovo-cel on track for submission in Q1 of 2023
Dec 10, 2022 11:30am
FDA panel backs bluebird's eli-cel despite FDA safety worries
Jun 9, 2022 6:33pm